[1] Roh MR, Eliades P, Gupta S, et al. Cutaneous melanoma in women [J]. Int J Womens Dermatol, 2017,16(3)∶S11-S15 [2] Coelho M, Soares-Silva C, Brandao D, et al.beta-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives [J]. J Cancer Res Clin Oncol, 2017, 143(2)∶275-291 [3] Wrobel LJ, Le Gal FA. Inhibition of human melanoma growth by a non-cardioselective beta-blocker [J]. J Invest Dermatol,2015, 135(2)∶525-531 [4] Dal Monte M, Casini G, Filippi L, et al.Functional involvement of beta3-adrenergic receptors in melanoma growth and vascularization [J].J Mol Med, 2013,91(12)∶1407-1419 [5] Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro [J]. Nature protocols, 2007,2(2)∶329-333 [6] 韩永付, 韩新光. 27例口腔颌面部恶性黑色素瘤临床分析[J].口腔医学研究,2014(6)∶537-539 [7] Weberpals J, Jansen L, Carr Pr, et al. Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis [J] . Cancer Treat Rev, 2016, 47∶1-11 [8] Childers Wk, Hollenbeak Cs, Cheriyath P. beta-Blockers Reduce Breast Cancer Recurrence and Breast Cancer Death: A Meta-Analysis [J]. Clinical breast cancer,2015;15(6)∶426-431 [9] Chen Y Z, Bai N, Bi J H, et al. Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1α dependent mechanisms[J]. Braz J Med Biol Res, 2017,50(12)∶e6138 [10] De Giorgi V, Grazzini M, Gandini S, et al. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma[J].Arch Intern Med, 2011,171(8)∶779-781 [11] Lemeshow S, Sorensen Ht, Phillips G, et al. beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study [J].Cancer Epidemiol Biomarkers Prev, 2011,20(10)∶2273-2279 [12] Lemeshow S, Sorensen Ht, Phillips G, et al. Beta-blocker usage after malignant melanoma diagnosis and survival: a populationbased nested case-control study[J]. Cancer Epidemiol Biomarkers Prev, 2011,20(10)∶2273-2279 [13] 王晓妍,张祥成,张薇薇,等.VEGF-A和VEGF-C在皮肤恶性黑色素瘤表达的临床病理意义[J].现代生物医学进展,2013,13(26)∶5082-5086 [14] Tang J, Li Z, Lu L, et al. beta-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy[J]Semin Cancer Biol,2013,23(6)∶533-542 [15] Miao C, Liang C, Zhu J, et al. Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis [J]. Oncotarget ,2017, 8(19)∶32309-32321 [16] 宋宁静,王晓楠,陈佳,等.MMP-2和MMP-9在皮肤恶性黑色素瘤中的表达及意义[J].中华全科医学,2011,09(8)∶1174-1174 [17] Kryza D, Debordeaux F, Azema L, et al. Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas [J]. PLoS One,2016,11(2)∶e0149387 [18] Pozzobon T, Goldoni G, Viola A, et al. CXCR4 signaling in health and disease [J]. Immunol Lett,2016 177∶6-15 [19] Mitchell B, Leone D, Feller K, et al. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 inprimary cutaneous melanoma-biomarkers of potential utility [J].Hum Pathol,2014,45(10)∶2094-2100 [20] Bi J, Li P, Li C, et al. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration [J].Tumor Biol,2016,37(3)∶4175-4182 |